产品
编 号：F186934
分子式：C15H23N3O4S
分子量：341.43
分子式：C15H23N3O4S
分子量：341.43
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
399
In-stock
结构图
CAS No: 15676-16-1
产品详情
生物活性：
Sulpiride is an orally active dopamine D2/D3 receptor antagonist. Sulpiride is an atypical antipsychotic agent of the benzamide family. Sulpiride can be used in research into anxiety, depression and breast cancer.
体内研究：
Sulpiride ( 50 mg/kg; 皮下注射; 单剂量) 在 Sprague-Dawley 大鼠中能增加大鼠的多巴胺水平。Sulpiride (5-20 mg/kg; 腹腔注射; 单剂量) 在帕金森病 (PD) 小鼠中剂量为 20 mg/kg 时会改善小鼠的记忆力但是会诱导焦虑。Sulpiride (25-100 mg/kg; 口服; 一天一次连续 18 天) 在携带 MCF-7/Adr 异种移植的 nu/nu 裸鼠中与地塞米松 (DEX) (HY-14648) (1 和 8 mg/kg) 联合使用时可以增强 DEX 的抗肿瘤活性，且对器官没有明显毒性。Animal Model: Sprague-Dawley rats model
Dosage:50 mg/kg
Administration:Subcutaneous injection (s.c.); Single dose.
Result:Caused dopamine concentrations in the dialysates to roughly double.
Animal Model:6-hydroxydopamine (6-OHDA) male NMRI mouse model of Parkinson’s disease (PD)
Dosage: 5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:Intraperitoneal injection (i.p.); Single dose
Result:Decreased %OAT (open-arm time) but had no significant effect on %OAE (open-arm entries) and locomotor activity.
Animal Model:Female nu/nu nude mouse models of breast cancer bearing MCF-7/Adr xenografts
Dosage:25 mg/kg, 50 mg/kg, 100 mg/kg
Administration:Oral gavage (p.o.); Once daily for 18 days. In combination with DEX (1 and 10 mg/kg; p.o.; Once daily for 18 days)
Result:When used in combination with DEX (1 mg/kg) at 50 m/kg, enhanced the tumor suppression rate (14.4%).When combined with DEX (8 mg/kg) at 25, 50, and 100 mg/kg, enhanced the tumor suppression rate by 30.2%, 27.55%, and 14.97%, respectively.
体外研究：
Sulpiride (20-50 μmol/L; 48 h) 在人乳腺癌 MCF-7/Adr 细胞中没有抗肿瘤活性，但可以以剂量依赖的方式降低体外和体内降低了癌症干细胞样细胞 (CSCs) 的比例。
Sulpiride is an orally active dopamine D2/D3 receptor antagonist. Sulpiride is an atypical antipsychotic agent of the benzamide family. Sulpiride can be used in research into anxiety, depression and breast cancer.
体内研究：
Sulpiride ( 50 mg/kg; 皮下注射; 单剂量) 在 Sprague-Dawley 大鼠中能增加大鼠的多巴胺水平。Sulpiride (5-20 mg/kg; 腹腔注射; 单剂量) 在帕金森病 (PD) 小鼠中剂量为 20 mg/kg 时会改善小鼠的记忆力但是会诱导焦虑。Sulpiride (25-100 mg/kg; 口服; 一天一次连续 18 天) 在携带 MCF-7/Adr 异种移植的 nu/nu 裸鼠中与地塞米松 (DEX) (HY-14648) (1 和 8 mg/kg) 联合使用时可以增强 DEX 的抗肿瘤活性，且对器官没有明显毒性。Animal Model: Sprague-Dawley rats model
Dosage:50 mg/kg
Administration:Subcutaneous injection (s.c.); Single dose.
Result:Caused dopamine concentrations in the dialysates to roughly double.
Animal Model:6-hydroxydopamine (6-OHDA) male NMRI mouse model of Parkinson’s disease (PD)
Dosage: 5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:Intraperitoneal injection (i.p.); Single dose
Result:Decreased %OAT (open-arm time) but had no significant effect on %OAE (open-arm entries) and locomotor activity.
Animal Model:Female nu/nu nude mouse models of breast cancer bearing MCF-7/Adr xenografts
Dosage:25 mg/kg, 50 mg/kg, 100 mg/kg
Administration:Oral gavage (p.o.); Once daily for 18 days. In combination with DEX (1 and 10 mg/kg; p.o.; Once daily for 18 days)
Result:When used in combination with DEX (1 mg/kg) at 50 m/kg, enhanced the tumor suppression rate (14.4%).When combined with DEX (8 mg/kg) at 25, 50, and 100 mg/kg, enhanced the tumor suppression rate by 30.2%, 27.55%, and 14.97%, respectively.
体外研究：
Sulpiride (20-50 μmol/L; 48 h) 在人乳腺癌 MCF-7/Adr 细胞中没有抗肿瘤活性，但可以以剂量依赖的方式降低体外和体内降低了癌症干细胞样细胞 (CSCs) 的比例。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备